Randomized Controlled Trial of the efficacy and safety of Ranibizumab and Aflibercept for polypoidal chroidal vasculopathy
Not Applicable
- Conditions
- polypoidal chroidal vasculopathy
- Registration Number
- JPRN-UMIN000010562
- Lead Sponsor
- Department of Ophthalmology, Ehime university faculty of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
PCV with type 2 CNV. severe glaucoma,diabetic macular edema,diabetic retinopath. intraocular surgery(<2 months). allergy to fluorescein or indocyanine green.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of best-collected visual acuity at month 6
- Secondary Outcome Measures
Name Time Method Change of polypoidal lesion, retinal edema,subretinal fluid,serous PED, the number of injection of medicine, side effect
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Ranibizumab and Aflibercept efficacy in polypoidal chroidal vasculopathy?
How do anti-VEGF therapies like Ranibizumab and Aflibercept compare to standard-of-care for PCV in clinical outcomes?
Which biomarkers correlate with treatment response to Ranibizumab or Aflibercept in PCV patients?
What are the long-term safety profiles of Ranibizumab versus Aflibercept in PCV treatment?
Are there combination therapies involving Ranibizumab or Aflibercept showing improved efficacy for PCV?